(1.20%) 5 070.55 points
(0.69%) 38 504 points
(1.59%) 15 697 points
(0.02%) $83.38
(1.27%) $1.835
(-0.27%) $2 335.70
(-0.15%) $27.32
(-0.17%) $921.20
(-0.42%) $0.934
(-0.70%) $10.91
(-0.80%) $0.803
(-0.24%) $93.19
Live Chart Being Loaded With Signals
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited, together with its subsidiaries, engages in the research, development, manufacture, and sale of Chinese patent and Western medicines, chemical raw materials, natural and biological medicines, and intermediates of chemical raw materials in the People's Republic of China and internationally...
Stats | |
---|---|
Today's Volume | 876 100 |
Average Volume | 746 143 |
Market Cap | 52.50B |
EPS | HKD0.600 ( 2023-10-30 ) |
Last Dividend | HKD0.813 ( 2023-06-14 ) |
Next Dividend | HKD0 ( N/A ) |
P/E | 7.45 |
ATR14 | HKD0.0260 (0.13%) |
Volume Correlation
Guangzhou Baiyunshan Correlation
10 Most Positive Correlations |
---|
10 Most Negative Correlations |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Guangzhou Baiyunshan Correlation - Currency/Commodity
Guangzhou Baiyunshan Financials
Annual | 2023 |
Revenue: | HKD75.52B |
Gross Profit: | HKD14.19B (18.79 %) |
EPS: | HKD2.50 |
Q4 | 2023 |
Revenue: | HKD17.33B |
Gross Profit: | HKD2.52B (14.52 %) |
EPS: | HKD0 |
Q3 | 2023 |
Revenue: | HKD18.21B |
Gross Profit: | HKD3.35B (18.37 %) |
EPS: | HKD0.600 |
Q2 | 2023 |
Revenue: | HKD18.34B |
Gross Profit: | HKD3.29B (17.94 %) |
EPS: | HKD0.560 |
Financial Reports:
No articles found.
Guangzhou Baiyunshan Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0.813 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | HKD0.0300 | 2000-04-20 |
Last Dividend | HKD0.813 | 2023-06-14 |
Next Dividend | HKD0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 25 | -- |
Total Paid Out | HKD6.04 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 3.35 | -- |
Div. Sustainability Score | 10.00 | |
Div.Growth Potential Score | 5.81 | |
Div. Directional Score | 8.67 | -- |
Year | Amount | Yield |
---|
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
8270.HK | Ex Dividend Junior | 2023-06-30 | Sporadic | 0 | 0.00% | |
2030.HK | Ex Dividend Junior | 2023-08-17 | Annually | 0 | 0.00% | |
1100.HK | Ex Dividend Knight | 2023-09-14 | Semi-Annually | 0 | 0.00% | |
0175.HK | Ex Dividend Knight | 2023-06-05 | Annually | 0 | 0.00% | |
3737.HK | Ex Dividend Knight | 2023-10-17 | Annually | 0 | 0.00% | |
1675.HK | Ex Dividend Knight | 2023-05-30 | Annually | 0 | 0.00% | |
0711.HK | Ex Dividend Junior | 2023-08-25 | Annually | 0 | 0.00% | |
2232.HK | Ex Dividend Knight | 2023-09-05 | Semi-Annually | 0 | 0.00% | |
1245.HK | Ex Dividend Junior | 2023-06-16 | Annually | 0 | 0.00% | |
0315.HK | Ex Dividend Knight | 2023-11-06 | Semi-Annually | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.0537 | 1.500 | 8.93 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0.0516 | 1.200 | 8.28 | 9.94 | [0 - 0.3] |
returnOnEquityTTM | 0.118 | 1.500 | 9.80 | 10.00 | [0.1 - 1] |
payoutRatioTTM | 0.391 | -1.000 | 6.09 | -6.09 | [0 - 1] |
currentRatioTTM | 1.545 | 0.800 | 7.27 | 5.82 | [1 - 3] |
quickRatioTTM | 1.176 | 0.800 | 7.79 | 6.23 | [0.8 - 2.5] |
cashRatioTTM | 0.588 | 1.500 | 7.84 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.152 | -1.500 | 7.47 | -10.00 | [0 - 0.6] |
interestCoverageTTM | 11.48 | 1.000 | 6.86 | 6.86 | [3 - 30] |
operatingCashFlowPerShareTTM | 5.44 | 2.00 | 8.19 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 4.44 | 2.00 | 7.78 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.342 | -1.500 | 8.63 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.188 | 1.000 | -0.202 | -0.202 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.0678 | 1.000 | -0.644 | -0.644 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0.741 | 1.000 | 7.00 | 7.00 | [0.2 - 2] |
assetTurnoverTTM | 0.961 | 0.800 | 6.93 | 5.54 | [0.5 - 2] |
Total Score | 11.53 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 7.18 | 1.000 | 9.38 | 0 | [1 - 100] |
returnOnEquityTTM | 0.118 | 2.50 | 9.87 | 10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 4.44 | 2.00 | 8.52 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 4.53 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 5.44 | 2.00 | 8.19 | 10.00 | [0 - 30] |
payoutRatioTTM | 0.391 | 1.500 | 6.09 | -6.09 | [0 - 1] |
pegRatioTTM | -0.898 | 1.500 | -9.32 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.117 | 1.000 | 9.57 | 0 | [0.1 - 0.5] |
Total Score | 5.81 |
Guangzhou Baiyunshan
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited, together with its subsidiaries, engages in the research, development, manufacture, and sale of Chinese patent and Western medicines, chemical raw materials, natural and biological medicines, and intermediates of chemical raw materials in the People's Republic of China and internationally. The company operates through four segments: Great Southern TCM, Great Commerce, Great Health, and Others. It is also involved in the wholesale, retail, import, and export of Western and Chinese medicines, and medical apparatus and instruments; and research and development, production, and sale of beverages, food, healthcare products, pre-packaging food, dairy products, tablets, capsules, lozenges, injections, tortoise herb jelly, etc. In addition, the company invests in health industry, such as medical care, health management, health preservation, elderly care, etc.; and provides commercial and advertising services. As of December 31, 2021, it had 154 retail chain pharmacy outlets, which included 22 Cai Zhi Lin pharmacy outlets, 36 Jian Min pharmacy outlets, 51 GPC Prescription Pharmacy outlets, and 23 Hainan Guangyao Chenfei Pharmaceutical Chain Co., Ltd outlets, as well as 22 retail stores. The company was formerly known as Guangzhou Pharmaceutical Company Limited and changed its name to Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited in August 2013. Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited was incorporated in 1997 and is based in Guangzhou, China.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators